CanSino Biologics, Inc. Class H (HK:6185)
:6185
Want to see HK:6185 full AI Analyst Report?
6185 Stock Chart & Stats
HK$44.94
-HK$0.10(-0.36%)
At close: 4:00 PM EST
HK$44.94
-HK$0.10(-0.36%)
Day’s Range― - ―
52-Week RangeHK$29.90 - HK$56.55
Previous CloseN/A
Volume470.05K
Average Volume (3M)609.75K
Market Cap
HK$12.95B
Enterprise ValueHK$12.08B
Total Cash (Recent Filing)HK$2.64B
Total Debt (Recent Filing)HK$1.29B
Price to Earnings (P/E)292.7
Beta1.43
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding132,670,900
10 Day Avg. Volume458,410
30 Day Avg. Volume609,752
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)1.60
Price to Sales (P/S)7.70
P/FCF Ratio-52.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.53
Revenue Forecast (FY)HK$1.44B
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthA large equity base and materially reduced debt improve financial flexibility and lower refinancing risk. This stronger leverage profile supports continued investments in manufacturing and R&D, and gives the company capacity to absorb shocks while pursuing long-cycle vaccine programs and tenders.
Return To ProfitabilityRe-establishing net profitability demonstrates the firm's ability to monetize its vaccine portfolio and manage costs. While margins remain modest, a positive bottom line can enable steadier investment planning, improve access to capital on better terms, and signal operational recovery to partners and customers.
Vaccine Platform And Commercialization CapabilitySpecialized vaccine expertise, an existing commercial product (adenovirus-vectored COVID-19 vaccine) and in-house manufacturing position the company to capture government procurement and partnership business. These structural capabilities create barriers to entry and recurring revenue potential from public health programs.
Bears Say
Weak Cash GenerationPersistently negative free cash flow despite an OCF recovery means the company has yet to demonstrate self-funding for capex and pipeline spend. Ongoing cash deficits increase reliance on external financing, raising dilution or debt risk and constraining long-term investment flexibility.
Earnings Volatility / Uneven ProfitabilityLarge swings in profitability and a still-negative EBIT suggest earnings are driven by episodic items or volatile demand. This undermines predictability for long-term margin sustainability, complicates strategic planning, and weakens metrics like ROE that matter for durable shareholder returns.
Revenue Dependence On Tenders And Pandemic DemandRevenue tied to government tenders and episodic pandemic vaccine demand creates structural cyclicality. Tender-driven sales are timing-dependent and can swing materially, making revenue and cash flow durability vulnerable until the company diversifies into steadier, non-pandemic vaccine streams or long-term supply contracts.
CanSino Biologics, Inc. Class H News
6185 FAQ
What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was HK$29.90 and its highest was HK$56.55 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
CanSino Biologics, Inc. Class H’s market cap is HK$12.95B.
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s upcoming earnings report date is Apr 28, 2026 which is today.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
Currently, no data Available
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Overvalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H pays a Notavailable dividend of HK$0.937 which represents an annual dividend yield of N/A. See more information on CanSino Biologics, Inc. Class H dividends here
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in HK:6185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CanSino Biologics, Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.91%
12-Months-Change
Fundamentals
Return on Equity
0.57%
Trailing 12-Months
Asset Growth
-5.61%
Trailing 12-Months
Company Description
CanSino Biologics, Inc. Class H
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―
Options Prices
Currently, No data available
---